草酸艾司西酞普兰联合米氮平对双相抑郁患者症状及认知功能的影响

The Influence of Escitalopram Oxalate Combined with Mirtazapine on Symptoms and Cognitive Function in Patients with Bipolar Depression

摘要

目的：基于症状控制及认知功能改善情况探讨草酸艾司西酞普兰（escitalopram oxalate，EO）联合米氮平应用于双相抑郁患者中的效果并予以分析。方法：2021年6月—2025年6月北京市房山区精神卫生保健院收治的100例双相抑郁患者，以密封信封抽签法分为试验组（n=50）及参考组（n=50）。参考组予以EO治疗，试验组则于EO的基础上加用米氮平治疗。对比两组疗效，临床症状，认知功能，睡眠质量，不良反应。结果：在总有效率方面对比，试验组高于参考组（94.00%vs 80.00%）（P<0.05）。给药8周后，两组汉密尔顿抑郁量表（Hamilton depression scale，HAMD）、杨氏躁狂量表（Young mania rating scale，YMRS）评分均低于给药前，且试验组低于参考组（均P<0.05）。给药8周后，试验组完全分类数、正确应答数评分均高于参考组，而错误应答数、持续错误数评分均低于参考组（均P<0.05）。给药8周后，两组匹兹堡睡眠质量指数（Pittsburgh sleep quality index，PSQI）评分均低于给药前，且试验组低于参考组（均P<0.05）。两组不良反应发生率对比差异无统计学意义（P>0.05）。结论：EO联合米氮平可显著改善双相抑郁患者的症状、认知功能及睡眠质量。

Abstract

Objective: To explore and analyze the effect of escitalopram oxalate (EO) combined with mirtazapine in patients with bipolar depression based on symptom control and cognitive function improvement. Methods: The research subjects were 100 patients with bipolar depression admitted to the Beijing Fangshan mental health center from June 2021 to June 2025. They were divided into the experimental group (n=50) and the reference group (n=50) by the sealed envelope lottery method. The reference group was treated with EO, while the experimental group was treated with EO combined with mirtazapine. The efficacy, clinical symptoms, cognitive function, sleep quality, and adverse reactions of the two groups were compared. Results: In terms of the total effective rate, the experimental group was higher than the reference group (P<0.05). Eight weeks after administration, the scores of the Hamilton depression scale (HAMD) and the Young mania rating scale (YMRS) in both groups were lower than those before administration, and the scores of the experimental group were lower than those of the reference group (all P< 0.05). Eight weeks after administration, the scores of complete classification and correct response in the experimental group were higher than those in the reference group, while the scores of incorrect response and persistent error were lower than those in the reference group (all P<0.05). Eight weeks after administration, the PSQI scores of both groups were lower than those before administration, and the scores of the experimental group were lower than those of the reference group (all P<0.05). The incidence of adverse reactions between the two groups was not significantly compared (P>0.05). Conclusion: EO combined with mirtazapine can significantly improve the symptoms, cognitive function and sleep quality of patients with bipolar depression.

关键词

双相障碍 / 抑郁 / 草酸艾司西酞普兰 / 米氮平 / 认知功能

Key words

bipolar disorder / depression / escitalopram oxalate / mirtazapine / cognitive function

参考文献

[1] 刘立滢, 郑胜丽, 陈光东. 血清色氨酸羟化酶糖原合成酶激酶3β水平对拉莫三嗪精准用药治疗青少年双相障碍抑郁发作的效果评估[J]. 中国药物与临床, 2024, 24(13): 857-861.

[2] 尚保华, 胡佳, 张刚, 等. 利培酮联合艾司西酞普兰治疗双相情感障碍抑郁发作的疗效及对血清尿酸的影响[J]. 四川医学, 2025, 46(8): 900-903.

[3] 刘超群, 刘立滢, 于明荣, 等. 拉莫三嗪治疗青少年双相障碍抑郁发作患者的药物不良反应及对代谢指标心理弹性的影响[J]. 中国药物与临床, 2025, 25(3): 164-168.

[4] 黄卫权, 蒋妍, 支胜利. 米氮平联合经颅直流电刺激治疗难治性抑郁症的疗效及对5—HT、BDNF水平的影响[J]. 中国现代医学杂志, 2025, 35(8): 92-96.

[5] 兰寒菊, 韦玉辉, 杨照奎. 改良电休克联合草酸艾司西酞普兰治疗双相情感障碍抑郁发作的疗效[J]. 中国实用神经疾病杂志, 2023, 26(12): 1548-1553.

[6] Lakshmi N Yatham, Sidney H Kennedy, Sagar V Parikh, et al. Canadian network for mood and anxiety treatments (CANMAT) and international society for bipolar disorders (ISBD) 2018 guidelines for the management of patients with bipolar disorder[J]. Bipolar Disord, 2018, 20(2): 97-170.

[7] 王铭锐, 云婷婷, 符丽红, 等. 小剂量喹硫平联合丙戊酸镁治疗双相情感障碍伴精神病性症状抑郁发作的效果及安全性观察[J]. 山东医药, 2022, 62(5): 71-73.

[8] 孙亚兴. 丙戊酸镁联合喹硫平治疗双相情感障碍的效果及对患者焦虑抑郁情绪、躁狂症状的影响[J]. 中国医学创新, 2023, 20(20): 115-118.

[9] 白晓光. 改良电休克联合碳酸锂治疗中老年双相情感障碍抑郁发作患者的效果[J]. 中国民康医学, 2021, 33(4): 86-88.

[10] 江婷婷, 刘伟, 刘会前. 帕罗西汀联合喹硫平治疗双相情感障碍抑郁发作的临床疗效[J]. 中南医学科学杂志, 2024, 52(4): 632-634.

[11] 陆占峰, 王建刚. 帕罗西汀联合草酸艾司西酞普兰治疗双相情感障碍抑郁发作的临床效果[J]. 临床医学研究与实践, 2022, 7(17): 81-83.

[12] 张晨昀. 焦虑伴抑郁症合并睡眠障碍患者应用不同剂量米氮平联合草酸艾司西酞普兰片治疗的效果与安全性研究[J]. 黑龙江医药, 2024, 37(6): 1365-1368.

[13] 孙刚, 张静. 艾司西酞普兰联合米氮平对老年抑郁症患者认知功能及血清NSE、MHPG水平的影响[J]. 检验医学与临床, 2024, 21(1): 91-94.

[14] 莫小恩. 米氮平联合草酸艾司西酞普兰治疗抑郁症伴睡眠障碍的疗效及对患者症状改善及睡眠质量的影响[J]. 世界睡眠医学杂志, 2021, 8(6): 1097-1098.

[15] 冯晓莉, 冯琳. 观察米氮平联合草酸艾司西酞普兰治疗抑郁症睡眠障碍患者的效果[J]. 中国实用医药, 2023, 18(12): 145-148.